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1. Introduction 
Over the past two decades, a striking increase in the number of people with type 2 diabetes 
has been observed. However, type 2 diabetes may remain undiagnosed for as long as 5 to 7 
years before the appearance of clinical symptoms. Insulin resistance (IR) is the best 
prediction factor of type 2 diabetes (Reaven, 1988; Erikson et al., 1989; Taylor et al., 1994; 
Henry, 2003). Therefore, early IR detection is of major clinical interest (McLaughlin & 
Reaven, 2003). Resistance to insulin-mediated glucose uptake occurs in most insulin 
sensitive tissues: the skeletal muscle, myocardium and adipose tissue. Mechanisms 
underlying this defect are still not fully understood (for review Biddinger & Kahn, 2006; 
Muoio & Newgard, 2008; Samuel et al., 2010). Until now, there is no available technique in 
clinical routine that allows the non-invasive assessment of insulin sensitivity in specific 
tissues under physiologic or pathophysiologic conditions. This kind of approach is possible 
using appropriate radiolabelled tracers that can be detected non-invasively. 
Indeed, a tracer is a compound that is chemically identical but separately detectable from 
the tracee, in this case glucose. Injected intravenously, the tracer is present in negligible 
quantities that do not themselves perturb metabolism, and its distribution in a given organ 
reflects the appearance or clearance rate of the tracee in this organ. 
Radiolabelled glucose analogues have been used for many years (D-glucose, L-glucose, 2-
deoxyglucose, 3-O-methyl-D-glucose) labelled with carbone 14 or tritium associated with 
hyperinsulinaemic euglycaemic clamp in animals, even in humans, to understand disease 
mechanisms and/or evaluate new therapies for type 2 diabetes. Modeling of washout 
curves of tracers allowed good estimation of glucose inward/outward transport and 
phosphorylation rates, but the use of these β- emitter radioisotopes is not always allowed in 
humans, moreover this technique does not permit to evaluate the regional location of 
metabolic events within tissues. In order to be less restrictive, the same approach has been 
developed in nuclear imaging, where radioactive tracers are injected to assess non-
invasively biological processes in vivo. Thus, a couple of tracers have been evaluated in 
combination with hyperinsulinaemic euglycaemic clamp, such as 18F-2-deoxy-D-glucose for 
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glucose metabolism (transport and phosphorylation), the most famous, or 11C-3-O-
methylglucose for glucose transport evaluation. Experimentally, with the recent 
development of nuclear imaging cameras with high resolution dedicated to small animals, 
and the increase of FDG disponibility, a couple of protocoles have been proposed to 
evaluate glucose uptake in vivo in rat and even in mice. But the necessity of the 
hyperinsulinaemic clamp conditions, which consist in a 3 hours perfusion of insulin and 
glucose, rendered this technique complicated and cumbersome for the patient and it cannot 
be used routinely. More recently, a new tracer, 123I-6-iodo-6-deoxy-D-glucose has been 
proposed to evaluate insulin-stimulated glucose transport in vivo using a more simple and 
shorter protocole (Briat et al., 2007). 
2. 18F-2-deoxy-D-glucose (FDG) 
The most widely used glucose analogue radiotracer in humans is 18F-2-deoxy-D-glucose 
(FDG), developed for positron emission tomography (PET) imaging. FDG, a glucose 
analogue quite similar to 2-Deoxy-Glucose (2DG), is recognized and transported into the 
cells by glucose transporters, and phosphorylated by hexokinase to form 18F-FDG-6-
phosphate (Bessell et al., 1972, 1973; Gallagher et al., 1977,1978). It cannot act as a substrate 
for further glycolysis and so rapidly accumulates in cells that have increased activity of 
hexokinase and increased glucose transporter levels, such as tumour cells. That is the reason 
why FDG is extensively used for PET imaging in oncology and has been evaluated and 
established in clinical routine for initial staging and assessment of response to cancer 
therapy.  
Since glucose transport defect in skeletal muscle is the main characteristic of insulin 
resistance, FDG and dynamic PET have also been developped to provide tissue-specific 
metabolic assessment of proximal steps of glucose metabolism in clinical investigations.  
We often heard about round trips between bench and bedside, the development of FDG is a 
perfect example. First, animal studies to assess in vivo insulin resistance in tissues such as 
skeletal muscle were performed during hyperinsulinaemic clamp with an injection of 14C-
2DG, dissection of tissues, and extraction of 2DG-6-P to count carbon 14. Ex vivo or in vitro, 
this tracer was so usefull in so many fields (i.e. diabetology, oncology, neurology, 
cardiology...) that an analogue usable in humans was extensively searched for many years. 
When 18FDG was obtained, PET imaging was not widely available. Nowadays with the 
increasing interest of this tracer in oncology, more and more medical centers are equiped 
with PET cameras and FDG is becoming more available and less expensive. Then PET 
cameras dedicated to small animals were developed and experimental studies can be 
performed.  
To assess global insulin sensitivity, the hyperinsulinaemic euglycaemic clamp is the gold 
standard (DeFronzo et al., 1981). To evaluate insulin stimulated glucose uptake in vivo 
within individual tissues, the used of 2-[14C]-DG injected as a bolus at the end of the 
insulin clamp, during steady state, has been developed first in concious rats by Kraegen 
and colleagues (Kraegen et al.,1983), and since then largely used, even in concious mice 
(Rossetti et al., 1997). Using this technique, tissue glucose metabolic rate or Rg’ can be 
assessed using plasma kinetic of 2DG over 45 minutes and tissue accumulation of 2-DG-6-
P at that time. The main limitation of this technique is the labelling of 2DG with carbon 14,  
a low energy β- emitter, which involves the death of the animal, dissection of the tissue 
and a laborious preparation to count the radioactivity. This method involves also 
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numerous blood samples which can represent another limitation especially in mice. FDG, 
labelled with a β+ emitter, can be detectable non invasively. This tracer is an analogue of 
2DG, i.e. it enters the cell using the same transporter as glucose and once inside the cell 
FDG is phosphorylated. The kinetics of its uptake reflect both the transport and 
phosphorylation steps. In human, FDG was first used to evaluate glucose metabolism in 
brain using dynamic PET-imaging associated with compartimental modeling developped 
by Sokoloff and colleagues (Sokoloff et al., 1977). This method was afterwards adapted to 
heart and skeletal muscle, associated with hyperinsulinaemic euglycaemic clamp (Phelps 
et al., 1978; Nuutila et al., 1992). A tree-compartment model was applied to estimate 
inward transport, outward transport and phosphorylation rates. Nuutila and colleagues 
used this technique to demonstrate that the glucose-FFA cycle operates in vivo in both 
heart and skeletal muscles in humans (Nuutila et al., 1992). In the same manner, Selberg 
and colleagues showed that patients with liver cirrhosis presented significant insulin 
resistance, and kinetic constants using the three-compartment model indicated reduced 
glucose transport in skeletal muscle but unchanged phosphorylation of glucose (Selberg et 
al., 1993). Another interesting study concerned the evaluation of regional insulin 
resistance in lean, obese, and obese with type 2 diabetic patients (Kelley et al., 1996). 
Kelley and colleagues showed that during a hyperinsulinaemic clamp associated with 
FDG-PET-imaging of skeletal muscle, the rate constant for glucose phosphorylation was 
similar in obese and lean subjects but reduced in diabetic patients. These in vivo 
assessment, associated with an immunohistochemical study of GLUT 4 performed ex vivo 
in muscle biopsies of patients indicated that impaired glucose transport plays a key role in 
insulin resistance of diabetes and obesity, and that an additional impairment of glucose 
phosphorylation is evident in the insulin resistance of type 2 diabetes (Kelley et al., 1996) 
(Figure 1). 
First experimental studies with FDG were performed in rabbits hindlimb that was secured 
between a single pair of coincidence gamma photon detectors positioned on the medial and 
lateral sides of the posterior thigh (Mossberg et al., 1989). The counting system consisted of 
two bismuth germanate oxide crystals interfaced to photomultiplier tubes. After signal 
amplification and filtering by discriminator units, the processed signals from each detector 
were sent to a coincidence logic unit. Animal has to be anesthetized, and FDG was injected 
as a bolus and then infused continuously through the experiment. Mossberg and colleagues 
used the method of graphical analysis of tissue and plasma radioactivity concentrations 
derived from Patlak and colleagues (Patlak & Blasberg, 1985) to quantitate the fractional rate 
of tracer phosphorylation. Briefly, the slope of the relationship between the integral of the 
plasma radioactivity concentration and the tissue radioactivity concentration during any 
given time interval yields the transfer constant, K, or the fractional rate of FDG 
phosphorylation. Multiplication of K by the plasma glucose concentration gives an index of 
the rate of glucose uptake (Rg’). During perturbation by electrical stimulation, an increased 
in the rate of tracer phosphorylation was observed, but no change of K was observed during 
hyperinsulinemia induced by a bolus of insulin. The next step was to introduced the 
hyperinsulinaemic clamp conditions in the method (Mossberg & Taegtmeyer, 1991, 1992). 
But the detection system was developed only by Mossberg and colleagues, and until the 
development of the first PET-cameras dedicated to small animals available on the market 
(2002 for Siemens Concorde R4), tissue insulin resistance was assessed with FDG mostly in 
humans. 
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Fig. 1. Glucose transport and phosphorylation rates assessed with 18FDG imaging and 
mathematical modeling in human skeletal muscle. In A, data from lean and obese 
nondiabetic and obese type 2 diabetic subjects during basal (shaded bars) and insulin 
stimulated (solid bars) conditions are shown for 18FDG clearance (K) into midthigh muscle; in 
B, the rate constant for transport of 18FDG (K1) is shown; in C, the rate constant for outward 
transport (k2) of 18FDG is shown; and in D, the rate constant for 18FDG phosphorylation (k3) 
during basal and insulin-stimulated conditions is shown. *Significant within-group 
difference comparing basal and insulin-stimulated values (P < 0.05). [Figure from Kelley et 
al, 1996 with permission]. 
Paternostro and colleagues studied insulin resistance in patients with a history of 
myocardial infarction (Paternostro et al., 1996). Using PET imaging technique, they 
measured heart and skeletal muscle blood flow with H215O and glucose uptake with FDG 
during euglycaemic hyperinsulinaemic clamp. The authors showed that in these patients, 
insulin resistance affects both the myocardium and skeletal muscle and is independent of 
blood flow. Numerous studies have been then performed to measure regional insulin 
resistance, mainly in heart and skeletal muscle in various patients, type 1 or type 2 diabetic 
(vom Dahl et al., 1993; Voipio-Pulkki et al., 1993), with or without hypertension (Yokoyama 
et al., 1998), obese or non obese (Kelley et al., 1999), with or without hypertriglyceridemia 
(Kobayakawa et al., 1999). The technique was also usefull to evaluate the impact of new 
therapy. For example, Yokoyama and colleagues showed that troglitazone, one of the first 
available thiazolidinedione, could improve whole-body insulin resistance through the 
improvement of skeletal muscle glucose uptake but not through a decline in plasma free 
fatty acid concentration in patients with type 2 diabetes (Yokoyama et al., 2001).  
In a way to simplify the technique, the activity in left ventricule or in aorta can be used as 
arterial input function (Iozzo et al., 2003 ; Keiding et al., 2000). Yokoyama and colleagues 
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proposed a even simpler method using static instead of dynamic imaging (Yokoyama et al., 
2003). 
The advent of small-animal PET technology allowed for the consecutive measurements of 
biochemical and physiological function in rodents. Sharp and colleagues provided an 
example of a cardiac imaging study using four radiotracers (15O-water, 1-[11C]-acetate, 1-
[11C]-palmitate and 1-[11C]-glucose) injected into normal rats (Sharp et al., 2005), 
demonstrating that rats can be used for multiple non invasive imaging studies with 
reproducible results over time with minimal or no change in hemodynamic or substrate 
levels. Using the same method, Welch and colleagues studied Zucker diabetic fatty (ZDF) 
rats showed that non invasive measurements of myocardial substrate metabolism were 
consistent with the expected early metabolic abnormalities that occur in this model of type 2 
diabetes mellitus (Welch et al., 2006). To summarize, when compared with their lean 
controls, the ZDF rat showed (a) elevated insulin, glucose, and FFA levels; (b) elevated FFA 
utilization and oxidation; (c) preserved myocardial glucose utilization; and (d) a trend 
toward a lower MVO2. However, the micro-blood sampling technique is necessary to 
provide accurate blood input function measurements, and when multiple tracer studies are 
performed in the same animal, this technique is limited by the number of blood samples that 
can be withdrawn in small animals. Kim and colleagues proposed a factor analysis (FA) 
technique for extracting the blood input function and myocardial time-activity curve from 
dynamic small-animal PET images of the rodent heart (Kim et al., 2006). Indeed, CT scans 
were not available on PET cameras dedicated to small animals at that time rendering the 
design of ROI in left ventricule rather difficult. The FA method has been used to decompose 
dynamic images into component images and to determine their time-activity curves by 
analysis of the variance in the data (Barber, 1980). It has been reported that the FA method 
successfully extracts the input functions and myocardial time-activity curves from dynamic 
PET images of canines, humans, and monkeys (Wu et al., 1995 ; 1996). In rat and mice, the 
FA method enables reliable quantification of physiologic or biologic information generated 
in small-animal PET-FDG studies and does not require the drawing of ROIs on small 
structures, such as a rodent heart or other small organs of interest, or repeated blood 
sampling (Kim et al., 2006). Using small-animal PET, Shogi and colleagues confirmed 
alterations in myocardial glucose utilization and validated PET measurement of Muscle 
Glucose Uptake (MGU) against gene and protein expression of GLUTs in the heart of an 
animal model of type 2 diabetes (Shogi et al., 2008). A new method has been validated in 
mice, a hybrid image and blood sampling (HIBS) method to derive the input function for 
quantification of microPET mice data. The HIBS algorithm derives the peak of the input 
function from the image (on the heart), which is corrected for recovery, while the tail is 
derived from 5 to 6 optimally placed blood sampling points (Shogi et al., 2007). The method 
is now well established in rodents, and can be used for example to validate new animal 
model of type 2 diabetes induced by diet closer to the human disease than genetic animal 
model available (Ménard et al., 2010).  
The compartmental model developed for FDG-PET imaging in skeletal muscle was initially 
used for PET data acquired in the central nervous system (CNS) and later modified. 
Bertoldo and colleagues proposed a muscle specific compartmental model, a modification 
that takes into account movement of FDG from plasma to interstitial space and from 
interstitial space into tissue via transmembrane glucose transport, as well as an irreversible 
compartment for formation of FDG-6-P (Bertoldo et al, 2001). Compared with the classic 
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model, the skeletal muscle-specific model reveals a more clearly defined effect of insulin on 
transmembrane glucose transport and an impairment of this response in obesity (Williams 
et al., 2003). 
Resistance to insulin also occurs in adipose tissue. But methods available to study directly 
adipose tissue metabolism in vivo are limited in human beings and its investigation has been 
carried out mainly by indirect measurements in the whole body or in cannulated limbs. 
FDG-PET has been combined with microdialysis to investigate adipose tissue glucose 
metabolism in human during insulin stimulation. Using this method, Virtanen and 
colleagues confirmed that obese patients had insulin resistance in both adipose tissue and 
skeletal muscle (Virtanen et al., 2001). 
More recently, Hirvonen and colleagues studied in humans the effects of insulin on brain 
glucose metabolism and cerebral blood flow in patients with impaired glucose tolerance and 
healthy subjects using FDG-PET associated to hyperinsulinemic clamp (Hirvonen et al., 
2011). Their results suggest that insulin stimulation of brain glucose metabolism is maximal 
at fasting concentrations in healthy subjects but not in patients with impaired glucose 
tolerance. This study showed that it could be a very usefull technique to evaluate the role of 
insulin in the brain and the possible insulin resistance in some conditions of this organ 
which has been for a long time considered as a non insulin sensitive tissue. 
3. 3-O-methyl-D-glucose (3-OMG) 
Skeletal muscle glucose uptake requires delivery of glucose to the sarcolemma, transport 
across this membrane, and the irreversible phosphorylation of glucose by hexokinase inside 
the cell. Because these three processes are so tightly coupled, it is difficult to determine the 
role of each of these steps in controlling the rate of muscle glucose uptake in vivo. An 
alternative approach is the measurement of the steady-state distribution of a non 
metabolizable glucose analogue across the sarcolemma, which allows the calculation of the 
transsarcolemmal glucose gradient. Numerous in vitro and in vivo experiments have shown 
that 3-O-methyl-D-glucose (3-OMG) is an ideal glucose analogue to probe transmembrane 
transport, sharing the same transport system as glucose and with equivalent affinity for 
glucose transport proteins (Narahara & Ozand, 1963; Buschiazzo et al., 1970; Carruthers, 
1990; O’Doherty et al., 1998).  
Cobelli and colleagues have used the perfused forearm and euglycaemic hyperinsulinaemic 
clamp techniques in combination with a dual-tracer injection to measure basal and insulin-
mediated glucose transport in normal subjects. L-[3H]glucose, which is not transported, was 
used to trace extracellular glucose kinetics, and 3-O-[14C]-methyl-D-glucose was used to 
monitor glucose transport across the cell membrane (Cobelli et al., 1989). A linear 
compartmental model was developed that accounts for blood flow heterogeneity. Using the 
same method, Bonadonna and colleagues have shown that transmembrane glucose transport 
was insulin resistant in the skeletal muscle of patients with type 2 diabetes and that this 
impairment was proportional to their degree of insulin resistance (Bonadonna et al., 1993). 
Halseth and colleagues adapted the technique for rat studies and showed that during exercice 
glucose phosphorylation becomes an important limitation to skeletal muscle (soleus) glucose 
uptake. During hyperinsulinaemia, both glucose delivery and glucose phosphorylation 
influence the rate of skeletal muscle glucose uptake more than under basal conditions (Halseth 
et al., 1998). The same group studied high fat diet rats showing a defect in skeletal muscle 
glucose transport under insulin conditions (Halseth et al., 2000), and the influence of muscle 
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fiber types on the rate of insulin-stimulated muscle glucose uptake, with glucose delivery and 
transport being the primary limiting factors in type II muscle (Halseth et al., 2001; Petersen et 
al., 2003). Recently, in vivo rates of transmembrane glucose transport and intracellular glucose 
phosphorylation were determined by analyzing the dilution curves of D-mannitol, [14C]3OMG, 
and D-[3-3H]glucose, using a multicompartmental model of glucose kinetics in forearm tissues 
(Pendergrass et al., 2007). The authors concluded that 1) obese non diabetic, lean type 2 diabetic, 
and offspring manifest moderate-to severe muscle insulin resistance and decreased insulin-
stimulated glucose transport and glucose phosphorylation in forearm muscle; these defects in 
insulin action are not further reduced by the combination of obesity plus diabetes; and 2) the 
increase in intracelullar glucose concentration under hyperinsulinaemic euglycaemic conditions 
in obese and type 2 diabetic groups suggests that the defect in glucose phosphorylation exceeds 
the defect in glucose transport (Pendergrass et al., 2007). 
Concerning imaging studies, the fact that emission from 18F can occur at either [18F]FDG or 
[18F]FDG-6-P, creates implicit uncertainty as to whether compartmental modeling achieves 
separate estimations of glucose transport and phosphorylation. Therefore dynamic PET 
imaging to isolate the step of transmembrane glucose transport in skeletal muscle based on 
chemical specificity of 3-OMG labeled with 11C has been proposed (Bertoldo et al., 2005). 
High quality imaging can be obtained and a clear effect of insulin to modulate the 
amplitude and configuration of tissue tracer activity was observed. Initial application 
indicated a robust effect of insulin to stimulate glucose transport in skeletal muscle of lean, 
healthy, insulin-sensitive volunteers (Bertoldo et al., 2005). Using the same method, Pencek 
and colleagues showed that in healthy volunteers there was robust dose-responsive insulin 
stimulation of glucose transport in skeletal muscle (Pencek et al., 2006) (Figure 2). 
 
 
Fig. 2. Glucose transport assessment with 11C-3-OMG in human skeletal muscle. MRI (A) 
and PET (B) images were carefully co-registered, and regions of interest (ROIs) were drawn 
within tibialis anterior and soleus muscle groups. ROIs were then applied to PET images to 
determine radioactivity accumulation within specific muscle groups. C: representative 
tissue activity curves during Basal (left), low-insulin (LO), and high-insulin (HI) conditions 
(right). D: representative tissue to plasma ratios (TPR) of 11C-3-OMG radioactivity. [Figure 
adapted from Pencek et al, 2006 with permission]. 
C
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There have been prior in vivo PET investigations in humans using [11C]3-OMG to study 
glucose transport across the blood-brain barrier (Vyska et al., 1985; Feinendegen et al., 
1986; Brooks et al., 1986a, 1986b). But the use of this tracer was limited by the fact that it is 
labelled with carbon 11, a short half-life radioisotope (t1/2= 20 minutes) produced by 
cyclotron, which undoubtedly explains why very few studies have been devoted to this 
compound.  
4. [123I]-6-deoxy-6-iodo-D-glucose (6DIG) 
Given the significant interest of a tracer to estimate alterations of glucose uptake in vivo, 
numerous researchers have tried for many years to develop glucose molecules labelled 
with a radioactive atom which is a pure -emitter, such as iodine 123, and which could be 
used routinely in Single Photon Emission Computed Tomography (SPECT), in all Nuclear 
Medicine centers (Kloster et al., 1983a, 1983b; Goodman et al., 1981a, 1981b; Lutz et al., 
1991; Magata et al., 1992; Koumanov et al., 1997a, 1997b; Perret et al, 2004). [123I]-6-deoxy-
6-iodo-D-glucose (6DIG) was first synthetized by Wassenar and colleagues, but the 
biological evaluation was limited to tumor uptake and not evaluated further (Wassenaar 
et al., 1973). The synthesis of 6DIG has been performed again more recently, and its 
biological behavior was carrefully evaluated. It was similar to that of 3-OMG (Henry et 
al., 1997a). It is transported into the cell by glucose transporters, but is not phosphorylated 
or further metabolized and is then free to leave the cell using the same transporters. The 
cellular uptake of this tracer allows true transport rates to be measured. Moreover, an in 
vitro study on the adipocytes of diabetic rats and obese mice showed that 6DIG, like 3-
OMG, could be used to determine alterations in glucose transport (Henry et al., 1997b). 
Our group then proposed to use 6DIG in vivo to assess insulin resistance by nuclear 
imaging. Studies in diabetic mice db/db and in insulin resistant fructose-fed rats showed 
that 6DIG was able to assess glucose transport defects in vivo (Slimani et al., 2002; Perret et 
al., 2003, 2007). In a preliminary study, we have shown in different rat models of insulin 
resistance that 6DIG could be used to assess non-invasively, using nuclear NaI probes, 
different degrees of cardiac insulin resistance without using hyperinsulinaemic clamp 
(Briat et al., 2007) (Figure 3). Based on these preliminary works, we further investigated 
the non-invasive assessment of cardiac and skeletal muscle insulin resistance using a 
gamma camera dedicated to small animals. We validated a simple protocol which is 
currently undergoing a clinical trial.  
5. Conclusion 
Nuclear imaging is routinely used to refine diagnosis in oncology and cardiology, but 
although his great potential not yet in diabetology. Probably because all the methods 
proposed until now were associated with complex protocoles. With the recent development 
of cameras for small animals, the development of new tracers is rendering easier and then 
can be proposed for  new clinical insights, or experimentally for new drug testing or 
physiopathology studies. Considering the complexity of mechanisms involved in insulin 
resistance development, such tools, giving non invasivelly fonctionnal informations in vivo 
are of great interest. 
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Fig. 3. Index of insulin sensitivity calculated as the ratio of 6DIG transport rate constant in 
insulin and basal conditions in rat myocardium (kin insulin / kin basal). White bars represent 
control animals (Wistar and lean ZDF rats) and solid bars insulin resistant animals (fructose-
fed Wistar and Zucker Diabetic Fatty rats). *Comparison of insulin-resistant rats versus 
control rats, Mann-Whitney test: *P < 0.05, ***P < 0.001. [Unpublished figure from the 
Ghezzi laboratory]. 
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